Despite the progressive decline of its incidence and mortality over the past decades, gastric cancer remains the forth most common cause of cancer-related death in Europe. While historically gastric adenocarcinoma has been classifed according to the Lauren classifcation in intestinal and diffuse subtype, the knowledge of the complex molecular mechanisms underlying its carcinogenesis has led to new molecular classifcations which can represent the starting point for the development of a personalized approach also in this disease. From a clinical point of view, while the addition of trastuzumab in the therapeutic armamentarium paved the way for the introduction of targeted therapy in the frst-line treatment, only recently the confrmation of the role of second-line therapy along with the approval of ramucirumab as a standard of care in this setting led to a new concept of continuum of care in gastric cancer. Furthermore, also the pivotal role of nutritional counseling and support both in early- and advanced-stage disease has been recently confrmed in many retrospective and prospective series.

Il trattamento di prima e seconda linea nel carcinoma gastrico / Gelsomino, Fabio; Spallanzani, Andrea; De Vita, Ferdinando; Di Bartolomeo, Maria; Gavazzi, Cecilia; Rimassa, Lorenza; Cascinu, Stefano. - In: RECENTI PROGRESSI IN MEDICINA. - ISSN 0034-1193. - 108:3(2017), pp. 120-127. [10.1701/2656.27234]

Il trattamento di prima e seconda linea nel carcinoma gastrico

Gelsomino, Fabio;Spallanzani, Andrea;GAVAZZI, CECILIA;Cascinu, Stefano
2017

Abstract

Despite the progressive decline of its incidence and mortality over the past decades, gastric cancer remains the forth most common cause of cancer-related death in Europe. While historically gastric adenocarcinoma has been classifed according to the Lauren classifcation in intestinal and diffuse subtype, the knowledge of the complex molecular mechanisms underlying its carcinogenesis has led to new molecular classifcations which can represent the starting point for the development of a personalized approach also in this disease. From a clinical point of view, while the addition of trastuzumab in the therapeutic armamentarium paved the way for the introduction of targeted therapy in the frst-line treatment, only recently the confrmation of the role of second-line therapy along with the approval of ramucirumab as a standard of care in this setting led to a new concept of continuum of care in gastric cancer. Furthermore, also the pivotal role of nutritional counseling and support both in early- and advanced-stage disease has been recently confrmed in many retrospective and prospective series.
2017
108
3
120
127
Il trattamento di prima e seconda linea nel carcinoma gastrico / Gelsomino, Fabio; Spallanzani, Andrea; De Vita, Ferdinando; Di Bartolomeo, Maria; Gavazzi, Cecilia; Rimassa, Lorenza; Cascinu, Stefano. - In: RECENTI PROGRESSI IN MEDICINA. - ISSN 0034-1193. - 108:3(2017), pp. 120-127. [10.1701/2656.27234]
Gelsomino, Fabio; Spallanzani, Andrea; De Vita, Ferdinando; Di Bartolomeo, Maria; Gavazzi, Cecilia; Rimassa, Lorenza; Cascinu, Stefano
File in questo prodotto:
File Dimensione Formato  
Il trattamento di prima e seconda linea nel carcinoma gastrico.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 225.43 kB
Formato Adobe PDF
225.43 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1157165
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact